AKAnna M. Kinsey

Anna M. Kinsey

*This is an algorithmically generated author record based on publicly available information.

Anna M. Kinsey has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    How COVID-19 has changed medical research funding

    by Patrick F. Chinnery, Jonathan J. Pearce, Anna M. Kinsey, Joanna M. Jenkinson, Glenn Wells, Fiona M. Watt

    Here, we consider how the lessons we learned in 2020 from funding COVID-19 research could have a long-term impact on the way that we fund medical research. We look back at how UK government funding for COVID-19 medical research evolved, beginning with the early calls for proposals in February that pump-primed funding for vaccines and therapeutics, and culminating in the launch of the government's National Core Studies programme in October. We discuss how the research community mobilized to submit and review grants more rapidly than ever before, against a background of laboratory and office closures. We also highlight the challenges of running clinical trials as the number of hospitalized patients fluctuated with different waves of the disease.


  • Open Access

    UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments

    by Rob J. Noad, Karl Simpson, Anthony R. Fooks, Roger Hewson, Sarah C. Gilbert, Mark P. Stevens, Margaret J. Hosie, Joann Prior, Anna M. Kinsey, Gary Entrican, et al.


  • Open Access

    Plasma Transthyretin as a Candidate Marker for Alzheimer's Disease

    by Latha Velayudhan, Richard Killick, Abdul Hye, Anna Kinsey, Andreas Güntert, Steven Lynham, Malcolm Ward, Rufina Leung, Anbarasu Lourdusamy, Alvina W.M. To, et al.

    Diagnosis of the progressive neurodegenerative disorder Alzheimer's disease (AD) can only definitively be made postmortem. The most promising AD biomarkers identified to date are found in cerebrospinal fluid (CSF). Among these, one of the most intere


  • Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment

    by Madhav Thambisetty, Yang An, Anna Kinsey, Deepthi Koka, Muzamil Saleem, Andreas Gϋntert, Michael Kraut, Luigi Ferrucci, Christos Davatzikos, Simon Lovestone, et al.


  • Open Access

    Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease

    by Madhav Thambisetty, Andrew Simmons, Abdul Hye, James Campbell, Eric Westman, Yi Zhang, Lars-Olof Wahlund, Anna Kinsey, Mirsada Causevic, Richard Killick, et al.

    Peripheral biomarkers of Alzheimer's disease (AD) reflecting early neuropathological change are critical to the development of treatments for this condition. The most widely used indicator of AD pathology in life at present is neuroimaging evidence of brain atrophy. We therefore performed a proteomic analysis of plasma to derive biomarkers associated with brain atrophy in AD. Using gel based proteomics we previously identified seven plasma proteins that were significantly associated with hippocampal volume in a combined cohort of subjects with AD (N = 27) and MCI (N = 17). In the current report, we validated this finding in a large independent cohort of AD (N = 79), MCI (N = 88) and control (N = 95) subjects using alternative complementary methods—quantitative immunoassays for protein concentrations and estimation of pathology by whole brain volume. We confirmed that plasma concentrations of five proteins, together with age and sex, explained more than 35% of variance in whole brain volume in AD patients. These proteins are complement components C3 and C3a, complement factor-I, γ-fibrinogen and alpha-1-microglobulin. Our findings suggest that these plasma proteins are strong predictors of in vivo AD pathology. Moreover, these proteins are involved in complement activation and coagulation, providing further evidence for an intrinsic role of these pathways in AD pathogenesis.


  • Proteome-Based Plasma Markers of Brain Amyloid-β Deposition in Non-Demented Older Individuals

    by Madhav Thambisetty, Romina Tripaldi, Joanna Riddoch-Contreras, Abdul Hye, Yang An, James Campbell, Jitka Sojkova, Anna Kinsey, Steven Lynham, Yun Zhou, et al.

    Blood-based markers reflecting core pathological features of Alzheimer's disease (AD) in pre-symptomatic individuals are likely to accelerate the development of disease-modifying treatments. Our aim was to discover plasma proteins associated with bra


  • Open Access

    Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease

    by Madhav Thambisetty, Andrew Simmons, Latha Velayudhan, Abdul Hye, James Campbell, Yi Zhang, Lars-Olof Wahlund, Eric Westman, Anna Kinsey, Andreas Güntert, et al.

    Peripheral compartments including blood and cerebrospinal fluid exhibit signals reflecting neuropathological changes in Alzheimer disease (AD).1,2 In cerebrospinal fluid, these include a decrease in amyloid-β peptide (Aβ) and an increase in total and phosphorylated tau concentrations,3 reflecting amyloid sequestration as plaques and neurofibrillary degeneration, respectively.4,5 Similarly, while numerous articles suggest that plasma concentrations of several metabolites and proteins might represent responses to neuropathological changes in AD,6-11 these findings have not been conclusively replicated.12 A limitation of such studies may be their reliance upon demonstrating changes between affected and unaffected people, a design of study that might identify secondary changes lacking relevance to core disease biology.


  • Open Access

    Protease Activated Receptors 1 and 4 Sensitize TRPV1 in Nociceptive Neurones

    by Vittorio Vellani, Anna M Kinsey, Massimiliano Prandini, Sabine C Hechtfischer, Peter Reeh, Pier C Magherini, Chiara Giacomoni, Peter A McNaughton

    Protease-activated receptors (PAR1–4) are activated by proteases released by cell damage or blood clotting, and are known to be involved in promoting pain and hyperalgesia. Previous studies have shown that PAR2 receptors enhance activation of TRPV1 but the role of other PARs is less clear. In this paper we investigate the expression and function of the PAR1, 3 and 4 thrombin-activated receptors in sensory neurones. Immunocytochemistry and in situ hybridization show that PAR1 and PAR4 are expressed in 10 – 15% of neurons, distributed across all size classes. Thrombin or a specific PAR1 or PAR4 activating peptide (PAR1/4-AP) caused functional effects characteristic of activation of the PLCp/PKC pathway: intracellular calcium release, sensitisation of TRPV1, and translocation of the epsilon isoform of PKC (PKCe) to the neuronal cell membrane. Sensitisation of TRPV1 was significantly reduced by PKC inhibitors. Neurons responding to thrombin or PAR1-AP were either small nociceptive neurones of the peptidergic subclass, or larger neurones which expressed markers for myelinated fibres. Sequential application of PAR1-AP and PAR4-AP showed that PAR4 is expressed in a subset of the PAR1-expressing neurons. Calcium responses to PAR2-AP were by contrast seen in a distinct population of small IB4+ nociceptive neurones. PAR3 appears to be non-functional in sensory neurones. In a skin-nerve preparation the release of the neuropeptide CGRP by heat was potentiated by PAR1-AP. Culture with nerve growth factor (NGF) increased the proportion of thrombin-responsive neurons in the IB4- population, while glial-derived neurotropic factor (GDNF) and neurturin upregulated the proportion of thrombin-responsive neurons in the IB4+ population. We conclude that PAR1 and PAR4 are functionally expressed in large myelinated fibre neurons, and are also expressed in small nociceptors of the peptidergic subclass, where they are able to potentiate TRPV1 activity.


  • Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease

    by Wendy Noble, Claire Garwood, John Stephenson, Anna M. Kinsey, Diane P. Hanger, Brian H. Anderton

    Alzheimer's disease (AD) is characterized by the presence of neurofibrillary tangles of hyperphosphorylated, aggregated tau protein and extracellular deposits of β‐amyloid peptide. Increased β‐amyloid levels are thought to precede tangle formation, but tau pathology is more closely related to neuronal death. Minocycline, a tetracycline derivative, has potent antiinflammatory, antiapoptotic, and neuroprotective effects in several models of neurodegenerative disease, including models of AD with amyloid pathology. We have used both in vitro and in vivo models of AD to determine whether minocycline may have therapeutic efficacy against tau pathology. In primary cortical neurons, minocycline prevents β‐amyloid‐induced neuronal death, reduces caspase‐3 activation, and lowers generation of caspase‐3‐cleaved tau fragments. Treatment of tangle‐forming transgenic mice (htau line) with minocycline results in reduced levels of tau phosphorylation and insoluble tau aggregates. The in vivo effects of minocycline are also associated with reduced caspase‐3 activation and lowered tau cleavage by caspase‐3. In tau mice, we find that conformational changes in tau are susceptible to minocycline treatment, but are not directly associated with the amount of tau fragments produced, highlighting a dissociation between the development of these pathological tau species. These results suggest a possible novel therapeutic role for minocycline in the treatment of AD and related tauopathies.— Noble, W., Garwood, C., Stephenson, J., Kinsey, A. M., Hanger, D. P., Anderton, B. H. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 23, 739–750 (2009)


  • Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat

    by K. R. Oliver, S. A. Kane, C. A. Salvatore, J. J. Mallee, A. M. Kinsey, K. S. Koblan, N. Keyvan‐Fouladi, R. P. Heavens, A. Wainwright, M. Jacobson, et al.

    Calcitonin gene‐related peptide (CGRP), adrenomedullin (ADM), amylin and calcitonin (CT) are structurally and functionally related neuropeptides. It has recently been shown that the molecular pharmacology of CGRP and ADM is determined by coexpression of one of three receptor activity‐modifying proteins (RAMPs) with calcitonin receptor‐like receptor (CRLR). Furthermore, RAMP proteins have also been shown to govern the pharmacology of the calcitonin receptor, which in association with RAMP1 or RAMP3, binds amylin with high affinity. In this study, we have cloned the rat RAMP family and characterized the pharmacology of rat CGRP and ADM receptors. Rat RAMP1, RAMP2 and RAMP3 shared 72%, 69% and 85% homology with their respective human homologues. As expected CRLR‐RAMP1 coexpression conferred sensitivity to CGRP, whilst association of RAMP2 or RAMP3 with CRLR conferred high affinity ADM binding. Using specific oligonucleotides we have determined the expression of RAMP1, RAMP2 and RAMP3 mRNAs in the rat central nervous system by in situ hybridization. The localization of RAMP mRNAs was heterogeneous. RAMP1 mRNA was predominantly expressed in cortex, caudate putamen and olfactory tubercles; RAMP2 mRNA was most abundant in hypothalamus; and RAMP3 was restrictively expressed in thalamic nuclei. Interestingly, in specific brain areas only a single RAMP mRNA was often detected, suggesting mutual exclusivity in expression. These data allow predictions to be made of where each RAMP protein may heterodimerize with its partner G‐protein‐coupled receptor(s) at the cellular level and consequently advance current understanding of cellular sites of action of CGRP, ADM, amylin and CT. Furthermore, these localization data suggest that the RAMP family may associate and modify the behaviour of other, as yet unidentified neurotransmitter receptors.